INSY - INSYS Therapeutics, Inc.

NasdaqGS - NasdaqGS Delayed Price. Currency in USD
0.2911
0.0000 (0.00%)
At close: 9:40AM EDT
Stock chart is not supported by your current browser
Previous CloseN/A
OpenN/A
BidN/A x N/A
AskN/A x N/A
Day's RangeN/A - N/A
52 Week Rangeundefined - undefined
VolumeN/A
Avg. VolumeN/A
Market CapN/A
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • GlobeNewswire

    FDA Accepts New Drug Application for INSYS Therapeutics’ Naloxone Nasal Spray for the Emergency Treatment of Known or Suspected Opioid Overdose

    INSYS Therapeutics, Inc. (OTCMKTS:INSYQ), announced today that its New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for its investigational, proprietary naloxone nasal spray for the emergency treatment of known or suspected opioid overdose in both adult and pediatric patients has been accepted for filing.  INSYS’ naloxone nasal spray is a single unit dose spray device that delivers 8mg naloxone dose. “The FDA’s acceptance of the NDA for INSYS’ proprietary formulation of a naloxone nasal spray is an important milestone in battling the U.S. opioid epidemic,” said Dr. Venkat Goskonda, chief scientific officer at INSYS Therapeutics. INSYS Therapeutics is a specialty pharmaceutical company using proprietary technology and capabilities to develop and commercialize innovative pharmaceutical products intended to address unmet medical needs and the clinical shortcomings of existing commercial products.

  • Opinion: Medical Marijuana Is a Terrible Investment
    Motley Fool

    Opinion: Medical Marijuana Is a Terrible Investment

    Medical marijuana drug developers are often smothered in hype and rarely deliver any reward.

  • Zynerba Up on Second Patent for Cannabidiol Candidate in 2019
    Zacks

    Zynerba Up on Second Patent for Cannabidiol Candidate in 2019

    Zynerba (ZYNE) gets a new U.S. patent covering methods of treating autism spectrum disorder with cannabidiol, a key compound of its lead pipeline candidate, Zygel.

  • Biotech Stock Roundup: Celgene Submits MS Drug to FDA, INSY & CBAY Crash
    Zacks

    Biotech Stock Roundup: Celgene Submits MS Drug to FDA, INSY & CBAY Crash

    Key highlights of the past week include regulatory approvals, collaborations and pipeline updates.

  • GlobeNewswire

    INSYS Therapeutics, Inc. Receives Court Approval of “First Day” Motions

    INSYS Therapeutics, Inc. (INSY) (“INSYS” or the “Company”), a specialty pharmaceutical development and distribution company, announced that on June 11, 2019 INSYS received interim approvals from the U.S. Bankruptcy Court for the District of Delaware for its First Day motions related to the Chapter 11 petitions filed on June 10, 2019. Andrew G. Long, Chief Executive Officer of INSYS Therapeutics, Inc., said, “This is an important step forward in our court-supervised process, which is intended to fairly and transparently address the Company’s legacy legal liabilities. The Court granted INSYS interim approval to continue its existing cash management system to collect and disburse cash generated by the business.

  • Insys Down on Bankruptcy News Amid Increasing Legal Expenses
    Zacks

    Insys Down on Bankruptcy News Amid Increasing Legal Expenses

    Insys (INSY) crashes as it files for bankruptcy protection amid rising legal settlement dues.

  • GlobeNewswire

    INSYS Therapeutics Initiates Court-Supervised Process to Facilitate Asset Sales and Address Legacy Liabilities

    INSYS Therapeutics, Inc. (INSY) (“INSYS” or the “Company”), a specialty pharmaceutical development and distribution company, announced today that INSYS has filed voluntary cases (the “Chapter 11 Cases”) under Chapter 11 of the U.S. Bankruptcy Code in the U.S. Bankruptcy Court in the District of Delaware (the “Court”) to facilitate the sale of substantially all of the Company’s assets and address the Company’s legacy legal liabilities. INSYS intends to continue operating its business in the ordinary course while it pursues these transactions through the court-supervised sale process.

  • 3 Marijuana Stocks I Wouldn't Touch With a 10-Foot Pole Right Now
    Motley Fool

    3 Marijuana Stocks I Wouldn't Touch With a 10-Foot Pole Right Now

    Some marijuana stocks are worth a serious look. These aren't.

  • 3 Marijuana Stocks Hitting All-Time Lows
    Motley Fool

    3 Marijuana Stocks Hitting All-Time Lows

    Though many cannabis investors are seeing green, these pot stocks have gone up in smoke.

  • Pfizer's (PFE) Epilepsy Drug Lyrica Fails in Phase III Study
    Zacks

    Pfizer's (PFE) Epilepsy Drug Lyrica Fails in Phase III Study

    Pfizer (PFE) announces failure of a phase III study evaluating Lyrica in patients with primary generalized tonic-clonic seizures, a form of epilepsy.